Back

Real-life adverse events with SGLT-2 inhibitors: different safety profiles according to their indications?

13 May 2024 (12:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Pharmacology and pharmacotherapy Antidiabetic Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Mr Omar Chebbo

Montpellier (France)

5 More presentations in this session

Presentation thumbnail
Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report
Doctor M. Feola (Mondovi, IT)
Abstract Slides
Presentation thumbnail
Assessing doctors' knowledge and confidence regarding SGLT2 inhibitor prescribing practices, side-effects, and ESC guidelines
Doctor E. Higgisson (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Efficacy of ARNI in patients using LVAD: a systematic review and meta-analysis
Doctor E. Hasabo (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Intravenous iron therapy for patients with heart failure and iron deficiency: an updated meta-analysis of randomized controlled trials
Mr G. Yeap (GB)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of SGLT2-i in patients using LVAD: a systematic review and meta-analysis
Doctor E. Hasabo (Galway, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacology and pharmacotherapy

The Event

Event poster

Heart Failure 2024

13 May 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Prescribing SGLT2 inhibitors in acute heart failure: considerations for dysglycemia status, heart failure phenotype, and kidney function
thumbnail
Congress Presentation
Cardiovascular diseases and type 2 diabetes mellitus: high heart failure risk and low rate contraindications to SGLT2i
thumbnail
Congress Presentation
The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources